Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker-Enfants Malades, F-75015, Paris, France; Université de Paris, VIFASOM, F-75004, Paris, France.
Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker-Enfants Malades, F-75015, Paris, France; Université de Paris, VIFASOM, F-75004, Paris, France; ASV Santé, F-92000, Gennevilliers, France.
Respir Med. 2021 May;181:106388. doi: 10.1016/j.rmed.2021.106388. Epub 2021 Apr 3.
To describe the characteristics of children treated with long term continuous positive airway pressure (CPAP) or noninvasive ventilation (NIV) in France.
Cross-sectional national survey.
Paediatric CPAP/NIV teams of 28 tertiary university hospitals in France.
Children aged <20 years treated with CPAP/NIV since at least 3 months on June 1st, 2019.
An anonymous questionnaire was filled in for every patient.
The data of 1447 patients (60% boys), mean age 9.8 ± 5.8 years were analysed. The most frequent underlying disorders were: upper airway obstruction (46%), neuromuscular disease (28%), disorder of the central nervous system (13%), cardiorespiratory disorder (7%), and congenital bone disease (4%). Forty-five percent of the patients were treated with CPAP and 55% with NIV. Treatment was initiated electively for 92% of children, while 8% started during an acute illness. A poly(somno)graphy (P(S)G) was performed prior to treatment initiation in 26%, 36% had a P(S)G with transcutaneous carbon dioxide monitoring (PtcCO), while 23% had only a pulse oximetry (SpO) with PtcCO recording. The decision of CPAP/NIV initiation during an elective setting was based on the apnea-hypopnea index (AHI) in 41% of patients, SpO and PtcCO in 25% of patients, and AHI with PtcCO in 25% of patients. Objective adherence was excellent with a mean use of 7.6 ± 3.2 h/night. Duration of CPAP/NIV was 2.7 ± 2.9 years at the time of the survey.
This survey shows the large number of children treated with long term CPAP/NIV in France with numerous children having disorders other than neuromuscular diseases.
描述在法国接受长期持续气道正压通气（CPAP）或无创通气（NIV）治疗的儿童的特征。
全国性横断面调查。
法国 28 家三级大学医院的儿科 CPAP/NIV 团队。
2019 年 6 月 1 日至少接受 CPAP/NIV 治疗 3 个月的年龄<20 岁的儿童。
对每位患者填写匿名问卷。
共分析了 1447 名（60%为男性）患儿的数据，平均年龄为 9.8±5.8 岁。最常见的基础疾病为：上呼吸道梗阻（46%）、神经肌肉疾病（28%）、中枢神经系统疾病（13%）、心肺疾病（7%）和先天性骨病（4%）。45%的患者接受 CPAP 治疗，55%接受 NIV 治疗。92%的患儿为择期治疗，8%的患儿在急性疾病期间开始治疗。26%的患儿在治疗开始前进行多导睡眠图（PSG）检查，36%的患儿进行 PSG 检查并进行经皮二氧化碳监测（PtcCO），23%的患儿仅进行脉搏血氧饱和度（SpO）检查并记录 PtcCO。在择期设置中启动 CPAP/NIV 的决策基于 41%的患儿的呼吸暂停低通气指数（AHI），25%的患儿基于 SpO 和 PtcCO，25%的患儿基于 AHI 和 PtcCO。客观依从性极好，平均使用时间为 7.6±3.2 小时/夜。在调查时，CPAP/NIV 的持续时间为 2.7±2.9 年。
本调查显示法国有大量儿童接受长期 CPAP/NIV 治疗，其中许多患儿存在神经肌肉疾病以外的疾病。
